Dr. Edward A. Ross received his M.D. degree from Boston University, completed his residency training at Vanderbilt University Medical Center, and received his fellowship training in nephrology at UCLA and the VA Wadsworth Hospital in Los Angeles. He is board certified in internal medicine and nephrology and has conducted research in the areas of renal dialysis, renal transplantation and hypertension.
Dr. Ross’ laboratory research interests focus on biomaterials and engineering in regard to renal replacement therapies. Currently his group is studying organ regeneration by the use of pluripotent precursor cells seeded into decellularized intact kidneys. Mouse and rat models are utilized to investigate stem cell differentiation and remodeling of scaffold basement membranes, with xenotransplantation being the ultimate goal. Previous research efforts from his multidisciplinary group have included the invention and licensing of a polyethylene glycol technology that can be used therapeutically for immunoadsorption and diagnostically for the detection of trace quantities of toxins.
Dr. Ross also has long-standing clinical research activity in improvements in extracorporeal renal replacement technology. His group has patented a safety device for detecting disconnection-associated venous hemorrhage in hemodialysis patients, as well as a photoplethysmography instrument to monitor vascular volume during ultrafiltration. Biomaterials and engineering projects have also included: the development bioimpedance technology for monitoring intra-abdominal fluid or hemorrhage; a new design for dialysis vascular access needles, and new phosphate-binding polymers. Direct clinical patient research studies have focused on the nutrition of dialysis patients. He has investigated the metabolism of a variety of nutrients, including pyridoxine, vitamin C, oxalate, glutathione, cysteine, and carnitine, and has published methods to improve nutrition in these patient populations.
The University of Central Florida, College of Medicine welcomed Dr. Ross as the chair of Internal Medicine in the summer of 2014. In his role at UCF, Dr. Ross leads the Department of Internal Medicine and provides strategic leadership at UCF Health, the college’s physician practice. Dr. Ross comes to UCF from the University of Florida, College of Medicine, where he was a tenured professor of medicine in the division of Nephrology, Hypertension and Renal Transplantation, director of the End Stage Renal Disease Program, and administrator of the Outpatient Chronic Dialysis Program at Shands Hospital. He also has served as vice chairman for clinical affairs in the Department of Medicine.
Willenberg BJ, Batich CD, Oca-Cossio J, Clapp WL, Abrahamson DR, Terada N, Ellison GW, Mathews CE, ROSS EA. Repurposed biological scaffolds: Kidney to pancreas. Organogenesis. 2015; 11:47-57.
Ayach T, Paugh-Miller JL, Nappo RW, ROSS EA. Postoperative hyperkalemia. Eur J Intern Med. 2015; 26:106-11.
ROSS EA and Damman K. Management of refractory heart failure. In: RJ Johnson and J Feehally (Eds). Comprehensive Clinical Nephrology, 5th edition, Elsevier, Amsterdam, 2014; p.867-72.
ROSS EA. Congestive renal failure: The pathophysiology and treatment of renal venous hypertension. J Card Fail. 2012; 18:930-8.
ROSS EA and Kazory A. Ultrafiltration therapy for cardiorenal syndrome: Physiologic basis and contemporary options. Blood Purif. 2012; 34:149-57.
ROSS EA, Abrahamson DR, St. John P, Clapp WL, Williams MJ, Terada N, Hamazaki T, Ellison GW, Batich CD. Mouse stem cells seeded into decellularized rat kidney scaffolds endothelialize and remodel basement membranes. Organogenesis. 2012; 8:49-55.
Alsabbagh M, Ejaz AA, Purich DL, ROSS EA. Regional citrate anticoagulation for slow continuous ultrafiltration: Risk of severe metabolic alkalosis. Clin Kidney J. 2012; 5:203-6.
ROSS EA, Reisfield GM, Watson MC, Chronister CW, Goldberger BA. Psychoactive “Bath Salts” intoxication with methylenedioxypyrovalerone. Am J Med. 2012; 125:854-8.
Sood P, Kumar G, Nanchal R, Sakhuja A, Ahmad S, Ali M, Kumar N, ROSS EA. Chronic kidney disease and end-stage renal disease predict higher risk of mortality in patients with primary upper gastrointestinal bleeding. Am J Nephrol. 2012; 35:216-24.
Kazory A, Bellamy FB, ROSS EA. Ultrafiltration for acute decompensated heart failure: Financial implications. Int J Cardiol. 2012; 154:246-9.
Kazory A and ROSS EA. Emerging therapies for heart failure: Renal mechanisms and effects. Heart Fail Rev. 2012; 17:1-16.
ROSS EA. Evolution of treatment strategies for calciphylaxis. Am J Nephrol. 2011; 34:460-7.
ROSS EA, Watson M, Goldberger B. “Bath salts” intoxication. N Engl J Med. 2011; 365:967-8.
Branham ML, Govender T, ROSS EA. Beta-2 microglobulin removal by immunoextraction and passive adsorption in high-flux dialyzers. J Biomim Biomater Tissue Eng. 2011; 11:35-44.
ROSS EA. What is the role for using sodium thiosulfate or bisphosphonates in the treatment of calciphylaxis? Semin Dial. 2011; 24:434-6.
ROSS EA, Bellamy FB, Hawig S, Kazory A. Ultrafiltration for acute decompensated heart failure: Cost, reimbursement & financial impact. Clin Cardiol. 2011; 34:273-7.
Branham ML and ROSS EA. Passive and facilitated transport of cyanocobalamin (Vitamin B12) across polymeric membranes in artificial kidneys. J Biomim Biomater Tissue Eng. 2011; 10:7-15.
Singh RP, Derendorf H, ROSS EA. Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol. 2011; 6:1155-9.
Sood P, Dass B, Bakuzonis C, ROSS EA. Intra-abdominal hypertension can be monitored with femoral vein catheters during CRRT and may cause access recirculation. Clin Nephrol. 2010; 74:223-8.
ROSS EA and Bellamy FB. Reducing patient financial liability for hospitalizations: The physician role. J Hosp Med. 2010; 5:160-2.
ROSS EA, Williams MJ, Hamazaki T, Terada N, Clapp WL, Adin C, Ellison GW, Jorgensen M, Batich CD. Pluripotent embryonic stem cells proliferate and differentiate when seeded into whole organ kidney scaffolds. J Am Soc Nephrol. 2009; 20:2338-47.
Kazory A and ROSS EA. Ultrafiltration for decompensated heart failure: Renal implications. Heart. 2009; 95:1047-51.
Kazory A and ROSS EA. Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol. 2009; 53:639-47.
Kazory A, Ejaz AA, ROSS EA. Ultrafiltration for heart failure: how fast should we move? Am Heart J. 2009; 157:205-7.
Kazory A and ROSS EA. Contemporary trends in the pharmacological and extracorporeal management of heart failure: A nephrologic perspective. Circulation. 2008; 117:975-983.
ROSS EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008; 28:97-106.
Fuehrlein B, Melker RB, ROSS EA. Alar photoplethysmography: A new methodology for monitoring fluid removal and carotid circulation during hemodialysis. J Clin Monit Comput. 2007; 2007; 21:211–218.
ROSS EA, Scott WE III, Odukale AA, Alba NA, Batich CD. Transient acid exposure increases Sevelamer HCl phosphate binding. J Pharm Sci. 2007; 96:2154-60.
ROSS EA, Alza RE, Jadeja NN. Hospital resource utilization that occurs with, rather than because of, kidney failure in patients with end-stage renal disease. Clin J Am Soc Nephrol. 2006; 1:1234-1240.
ROSS EA, Briz C, Sadleir JR. Method for detecting the disconnection of an extracorporeal device using a patient’s endogenous electrical voltages”. Kidney Int. 2006; 69:2274-7.
ROSS EA, Hollen TL and Fitzgerald BM. Observational study of an Arts-In-Medicine program in an outpatient hemodialysis unit. Am J Kidney Dis. 2006; 47:462-8.
Bihorac A and ROSS EA. Continuous venovenous hemofiltration with citrate-based replacement fluid: Efficacy, safety, and impact on nutrition. Am J Kidney Dis. 2005; 46:908-918.
ROSS EA, Savage KA, Utley LJ, Tebbett IR. Insect repellent interactions: Sunscreens enhance DEET (N,N-diethyl-M-toluamide) absorption. Drug Metab Dispos 2004;32:783-785.
ROSS EA, Batich CD, Clapp WL, Sallustio JE, Lee NC. Tissue adhesion to bioactive glass-coated silicone tubing in a rat model of peritoneal dialysis catheters and catheter tunnels. Kidney Int 2003;63:702-708.
ROSS EA, Pittman TB, Koo LC. Strategy for the treatment of noncompliant hypertensive hemodialysis patients. Int J Artif Organs 2002;25:1061-1065.
ROSS EA, Branham ML, Tebbett IR. High mass clearance of autoantibodies from a murine model of lupus nephritis by immunoadsorption using star-configured polyethylene glycols. J Biomed Mater Res 2001;55:114-120.
ROSS EA, Szabo NJ, Tebbett IR. Lead content of calcium supplements. JAMA 2000; 284:1425-1429.
ROSS EA, Verlander JW, Koo LC, Hawkins IF. Minimizing hemodialysis vascular access trauma with an improved needle design. J Am Soc Nephrol 2000; 11:1325-1330.
ROSS EA, Branham ML, Tebbett IR. Optimization of ligand presentation for immunoadsorption using star-configured polyethylene glycols. J Biomed Mater Res 2000; 51:29-36.
ROSS EA and Koo LC. Improved nutrition after the detection and treatment of occult gastroparesis in nondiabetic dialysis patients. Am J Kidney Dis 1998; 31:62-66.
ROSS EA, Koo LC, Moberly JB. Low whole blood and erythrocyte levels of glutathione in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1997; 30:489-494.
Rutledge DR, Sun Y, ROSS EA. Polymorphisms within the atrial natriuretic peptide gene in essential hypertension. J Hypertens 1995; 13:953-955.
Rutledge DR, Kubilis P, Browe CS, ROSS EA. Polymorphism of the angiotensin I converting enzyme gene in essential hypertensive patients. Biochem Molecular Biol Intl 1995; 35:661-668.
Rutledge DR, Browe CS, ROSS EA. Frequencies of the angiotensinogen gene and angiotensin I converting enzyme (ACE) gene polymorphisms in African Americans African Americans. Biochem Molecular Biol Intl 1994; 34:1271-1275.
Rutledge DR, Browe CS, Kubilis P, ROSS EA. Analysis of two variants of the angiotensinogen gene in essential hypertensive African-Americans. Am J Hypertension 1994; 7:651-654.